UBS Maintains Buy on ACM (Aecom) Feb 2026, Price Target Raised to $145

UBS on Feb 10, 2026 maintained a Buy on ACM (Aecom) and raised its price target to $145. The ACM analyst rating by UBS signals continued conviction in Aecom’s backlog and margins after the Q1 call. Investors should note UBS kept the rating while nudging the target from $143 to $145, a measured move that reflects steady fundamental views rather than a dramatic outlook change. This update ties directly to analyst expectations and broader consensus data.

ACM analyst rating: UBS action and details

UBS maintained a Buy on ACM and raised its target to $145 from $143 on Feb 10, 2026. The note was reported by The Fly and flags steady confidence in Aecom’s project pipeline source.

Market reaction and short-term stock movement

The UBS move came with a reported intraday price change of -1.4% ($-1.46) following the update. That decline shows analysts’ commentary can be outweighed by other near-term forces, such as broader market flows or earnings reads. Aecom’s market cap stands at $13,681,663,195, giving context to how analyst notes can influence large-cap stock trading.

Analyst context and historical coverage for ACM analyst rating

Consensus data shows an average target price of 126.73 across 16 analyst ratings and an “Overweight” or similar tilt in recent aggregates. MarketWatch lists the sector averages and the analyst consensus figures, which help frame UBS’s target above the peer consensus source.

What the maintained Buy rating means for investors

A maintained Buy from UBS means analysts still expect outperformance versus peers or the market. For investors, it signals confidence in revenue visibility, project execution, and margin trends but not an aggressive shift in view. Investors should weigh UBS’s view against the consensus and their time horizon.

Price target comparison and valuation implications for ACM upgrade view

UBS’s $145 target sits $18.27 above the MarketWatch average target of 126.73. That gap equals about 14.42% higher than the consensus target, suggesting UBS sees more upside than the median analyst. The difference highlights valuation variation across firms and the need to review assumptions on growth and margins.

Meyka AI grade and how we frame the ACM analyst rating

Meyka AI rates ACM with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our platform combines real-time analyst tracking with proprietary scoring to show where UBS’s update sits relative to peers. See our coverage on the Meyka ACM page for live updates.

Final Thoughts

UBS’s Feb 10, 2026 note kept a Buy on ACM while nudging the price target to $145, a measured endorsement rather than a change of stance. The ACM analyst rating confirms ongoing analyst confidence, even as the stock dipped -1.4% ($-1.46) on the update. Investors should view the UBS move as one input among 16 analyst views and a consensus average target of 126.73. Compare the $145 UBS target to the consensus to assess upside and risk.

For investors, the practical step is to align UBS’s assumptions with your own time horizon and risk appetite. The $145 target sits $18.27 above consensus, implying a 14.42% premium over the average target and leaving room for differing forecasts on backlog conversion and margin recovery. Meyka AI’s live grade B+ offers a concise snapshot of ACM’s profile, but it is not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.